Generic Name

Pramipexole

FDA approval date: October 08, 2010
Classification: Nonergot Dopamine Agonist
Form: Tablet

What is Pramipexole?

PRAMIPEXOLE DIHYDROCHLORIDE tablets is a non-ergot dopamine agonist indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease .

Approved To Treat

Top Global Experts

There are no experts for this drug

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances

Related Clinical Trials

There is no clinical trials being done for this treatment

Related Latest Advances

In brief: Adjunctive pramipexole for treatment-resistant depression.
In brief: Adjunctive pramipexole for treatment-resistant depression.
Journal: The Medical letter on drugs and therapeutics
Published: October 08, 2025
On the mechanisms of dopamine receptor agonists in restless legs syndrome.
On the mechanisms of dopamine receptor agonists in restless legs syndrome.
Journal: Sleep
Published: August 07, 2025
Genetic changes in regulatory immune cells induced by pramipexole and rotigotine: implications for the treatment of Parkinson's disease.
Genetic changes in regulatory immune cells induced by pramipexole and rotigotine: implications for the treatment of Parkinson's disease.
Journal: Inflammopharmacology
Published: August 04, 2025
View All Latest Advances